News

Qisda's medical business surpasses NT20bn

Cumulative consolidated revenue for 2022 was NT$239.829 billion, close to the NT$240 billion mark, an increase of NT$13.9 billion over 2021 and a 6% annual growth rate.

Read more

Jan 06, 2023

PBF's kidney drug knocks the door open in Europe, royalties expected

Cnyes.com

Jan 06, 2023

Handa Pharma to launch four products in US by 2023, aiming at $1bn in three years

Investor.com.tw

Jan 04, 2023

Ever Supreme Bio Technology nets NT$600M in revenue, a 43% growth YoY

Economic Daily

Jan 04, 2023

EirGenix takes a leap in 2023, looking to approval of HER2 biosimilar EG12014

Commercial Times

Jan 04, 2023

PharmaEssentia accelerates NDA overseas to boost operation

Moneydj.com

Jan 03, 2023

Taiwan's pharmaceutical industry sees spring ahead with high profitability

Commercial Times

Jan 03, 2023

Yun Yen takes over as Chairman of OBI Pharma

Commercial Times

Dec 30, 2022

TWi Pharmaceuticals' ANDA for Dicyclomine Hydrochloride Capsule (equivalent to BENTYL ®) has been officially approved by FDA

TWi Pharmaceuticals

Dec 29, 2022

Oneness Biotech's wound cream to launch in Q1, 2023

Investor.com.tw